These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314 [TBL] [Abstract][Full Text] [Related]
27. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505 [TBL] [Abstract][Full Text] [Related]
29. The genetics of Parkinson's syndromes: a critical review. Hardy J; Lewis P; Revesz T; Lees A; Paisan-Ruiz C Curr Opin Genet Dev; 2009 Jun; 19(3):254-65. PubMed ID: 19419854 [TBL] [Abstract][Full Text] [Related]
30. (123)I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. Bostantjopoulou S; Katsarou Z; Gerasimou G; Costa DC; Gotzamani-Psarrakou A Hell J Nucl Med; 2008; 11(3):157-9. PubMed ID: 19081858 [TBL] [Abstract][Full Text] [Related]
31. Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Tokutake T; Ishikawa A; Yoshimura N; Miyashita A; Kuwano R; Nishizawa M; Ikeuchi T Parkinsonism Relat Disord; 2014 Feb; 20(2):262-4. PubMed ID: 24315198 [No Abstract] [Full Text] [Related]
32. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093 [TBL] [Abstract][Full Text] [Related]
33. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675 [TBL] [Abstract][Full Text] [Related]
36. The Lewy body in Parkinson's disease. Forno LS Adv Neurol; 1987; 45():35-43. PubMed ID: 3030070 [TBL] [Abstract][Full Text] [Related]
37. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
38. Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease. Basu S; Je G; Kim YS Exp Mol Med; 2015 Aug; 47(8):e179. PubMed ID: 26315598 [TBL] [Abstract][Full Text] [Related]
39. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. Attems J; Jellinger KA Neuropathol Appl Neurobiol; 2008 Aug; 34(4):466-7. PubMed ID: 18282157 [No Abstract] [Full Text] [Related]
40. The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. Hofer A; Berg D; Asmus F; Niwar M; Ransmayr G; Riemenschneider M; Bonelli SB; Steffelbauer M; Ceballos-Baumann A; Haussermann P; Behnke S; Krüger R; Prestel J; Sharma M; Zimprich A; Riess O; Gasser T J Neural Transm (Vienna); 2005 Sep; 112(9):1249-54. PubMed ID: 15622440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]